Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving the identification of frail elderly newly diagnosed multiple myeloma patients.
Stege CAM, Nasserinejad K, Klein SK, Timmers GJ, Hoogendoorn M, Ypma PF, Nijhof IS, Velders GA, Strobbe L, Durdu-Rayman N, Westerman M, Davidis-van Schoonhoven MA, van Kampen RJW, Beeker A, Koster A, Dijk AC, van de Donk NWCJ, van der Spek E, Leys RBL, Silbermann MH, Groen K, van der Burg-de Graauw NCHP, Sinnige HAM, van der Hem KG, Levenga H, Bilgin YM, Sonneveld P, Levin MD, Zweegman S. Stege CAM, et al. Among authors: levenga h. Leukemia. 2021 Sep;35(9):2715-2719. doi: 10.1038/s41375-021-01162-z. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589752 Clinical Trial. No abstract available.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP; HOVON CLL study group. Kersting S, et al. Among authors: levenga h. Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5. Lancet Haematol. 2022. PMID: 35240075 Clinical Trial.
Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H. Hobo W, et al. Among authors: levenga h. Cancer Immunol Immunother. 2013 Aug;62(8):1381-92. doi: 10.1007/s00262-013-1438-2. Epub 2013 Jun 2. Cancer Immunol Immunother. 2013. PMID: 23728352 Free PMC article. Clinical Trial.
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL, van Eijk R, Böhringer S, van Wezel T, Raghoo R, Ruano D, Jansen PM, Briaire-de Bruijn I, de Groot FA, Kleiverda K, Te Boome L, Terpstra V, Levenga H, Nicolae A, Posthuma EFM, Focke-Snieders I, Hardi L, den Hartog WCE, Bohmer LH, Hogendoorn PCW, van den Berg A, Diepstra A, Nijland M, Lugtenburg PJ, Kersten MJ, Pals ST, Veelken H, Bovée JVMG, Cleven AHG, Vermaat JSP. de Groen RAL, et al. Among authors: levenga h. Blood Adv. 2021 Oct 12;5(19):3760-3775. doi: 10.1182/bloodadvances.2021005215. Blood Adv. 2021. PMID: 34478526 Free PMC article.
A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR.
Broen K, Levenga H, Vos J, van Bergen K, Fredrix H, Greupink-Draaisma A, Kester M, Falkenburg JH, de Mulder P, de Witte T, Griffioen M, Dolstra H. Broen K, et al. Among authors: levenga h. PLoS One. 2011;6(6):e21699. doi: 10.1371/journal.pone.0021699. Epub 2011 Jun 28. PLoS One. 2011. PMID: 21738768 Free PMC article.
Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R, De Mulder PH, van de Wiel-van Kemenade E, Schaap N, de Witte T, Dolstra H. Levenga H, et al. Bone Marrow Transplant. 2007 Sep;40(6):585-92. doi: 10.1038/sj.bmt.1705777. Epub 2007 Jul 16. Bone Marrow Transplant. 2007. PMID: 17637687 Clinical Trial.
Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A, de Witte T, Dolstra H, Raymakers R. Levenga H, et al. Biol Blood Marrow Transplant. 2010 Mar;16(3):320-32. doi: 10.1016/j.bbmt.2009.10.006. Epub 2009 Oct 14. Biol Blood Marrow Transplant. 2010. PMID: 19835972 Free article. Clinical Trial.
14 results